SAN FRANCISCO: Study findings indicate no clinically significant effect of avagacestat on cerebrospinal fluid amyloid biomarkers or clinical measures of prodromal Alzheimer’s disease.

“Avagacestat (BMS-708163) is an oral γ-secretase inhibitor designed for the selective inhibition of ß-amyloid (Aß) synthesis relative to processing of Notch substrates. Phase Read More »

CHICAGO: Anavex Life Sciences Corp, a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that patient enrolment for the Phase 2a clinical trial of ANAVEX 2-73 has been completed Read More »

LOS ANGELES: In a study, certain common drugs were linked to an increased risk of developing some form of dementia such as Alzheimer’s disease.

The study found that common drugs such as the following are tied to increased incidence of dementia over time:

• Diphenhydramine – the

DALLAS: Researchers published results of a novel study of the functional activation patterns of working memory after mild traumatic brain injury (TBI).

This study, the first to enrol subjects during their initial evaluation in the emergency room, provides new information on the acute effects of Read More »